Novo Nordisk, Inc.: Semaglutide Tablet to be discontinued
Novo Nordisk, Inc.: Semaglutide Tablet to be discontinued. Its amount of 3 is above the median of 3 (62nd percentile). Dated 154 days ago, it serves as a historical benchmark. Score 50/100. As of 2026-11-04, from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list).
Data as of · Compiled by Zalwin from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)
amount: 3 · 62th percentile of 353 DrugShortagePulse records · 1.0x the median
Free preview: all 12 published fields of this record are shown below. Locked: 352 related DrugShortagePulse records and the 5-column CSV export.
| Field | Value |
|---|---|
| Manufacturer | Novo Nordisk, Inc. |
| Drug | Semaglutide Tablet |
| Dosage form | Tablet |
| Therapeutic category | Endocrinology/Metabolism |
| Status | To Be Discontinued |
| Stage | Manufacturer discontinuation |
| Presentations affected | 3 |
| Package NDCs | 0169-4307-30, 0169-4314-30, 0169-4303-30 |
| Manufacturer supply note | Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets. |
| Discontinued date | 2026-06-04 |
| First posted | 2026-06-04 |
| Updated | 2026-06-04 |
| amount percentile | 62th of 353 (median 3, 1.0x median) |
| Peer records CSV (353 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Novo Nordisk, Inc.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Novo Nordisk + all 353 records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Manufacturer · Drug · Stage · Availability · Updated · official source URL
- Source agency: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)
- Record date: 2026-06-04
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top DrugShortagePulse records: Sanofi-Aventis U.S. LLC · Fresenius Kabi USA, LLC · Hospira, Inc., a Pfizer Company · Fresenius Kabi USA, LLC · Hospira, Inc., a Pfizer Company · Browse all by state and category →
LIVE PUBLIC DATA Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) · Last refreshed: Wed, 04 Nov 2026 06:10:12 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
50 / 100 Score
- The manufacturer is leaving the market.
What is the DrugShortagePulse record for Novo Nordisk, Inc.?
Novo Nordisk, Inc.'s Semaglutide Tablet is on the FDA drug shortage list. Manufacturer discontinuation. Last updated 2026-06-04.
How does Novo Nordisk, Inc. compare to other DrugShortagePulse records?
Its amount of 3 sits in the upper half (62th percentile) of 353 records; the median is 3. It is 154 days old; check the official source for later updates before acting.
Novo Nordisk, Inc. vs. top 3 peers
| Organization | Amount | Percentile | Record date |
|---|---|---|---|
| Novo Nordisk, Inc. | 3 | 62nd | 2026-06-04 |
| Baxter Healthcare | 3 | 62nd | 2026-10-30 |
| Baxter Healthcare | 2 | 49th | 2026-10-30 |
| Baxter Healthcare | 2 | 49th | 2026-10-30 |
Related records
- Baxter Healthcare
- Baxter Healthcare
- Baxter Healthcare
- Sanofi-Aventis U.S. LLC
- Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
- Fresenius Kabi USA, LLC
- Fresenius Kabi USA, LLC
- Par Health, USA LLC
- Hospira, Inc., a Pfizer Company
- Merck Sharp & Dohme LLC
- Eli Lilly and Co.
- Eli Lilly and Co.
DrugShortagePulse: Manufacturer discontinuation DrugShortagePulse: Endocrinology/Metabolism
How to monitor Novo Nordisk, Inc. and peer endocrinology/metabolism records
Get new DrugShortagePulse records like Novo Nordisk, Inc. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new shortages in your categories
DrugShortagePulse emails new and changed FDA drug shortages matching your therapeutic categories.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.